Video yรผkleniyor...

Video Yรผklenemedi

๐‚๐š๐ง ๐š๐ง ๐ข๐ง๐ฃ๐ž๐œ๐ญ๐ž๐ ๐ฏ๐š๐œ๐œ๐ข๐ง๐ž ๐ฉ๐ซ๐ž๐ฏ๐ž๐ง๐ญ ๐ญ๐ซ๐š๐ง๐ฌ๐ฆ๐ข๐ฌ๐ฌ๐ข๐จ๐ง ๐จ๐Ÿ ๐š ๐ซ๐ž๐ฌ๐ฉ๐ข๐ซ๐š๐ญ๐จ๐ซ๐ฒ ๐ฏ๐ข๐ซ๐ฎ๐ฌ โ“ In the last episode of the The Darkhorse Podcast , Bret Weinstein explains the difference between Mucosal Immunity and Blood Immunity, and how that relates to injected vaccines. Open ๐Ÿงต- Thread - #MedicalFreedom โ‡’

20,116 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce โ€ขvia X (Twitter)

0 Yorum

Yorum bulunmuyor

Orijinal gรถnderinin yorumlarฤฑ burada gรถrรผnecek

Benzer Videolar

I asked Grok to explain why intramuscular vaccines don't work against respiratory viruses. The answer may surprise you; The explanation for why intramuscular (IM) vaccines might not be as effective against respiratory viruses involves understanding both the nature of the immune response and how vaccines work: 1. Site of Action and Immune Response Location: ๐Ÿ‘‰Respiratory Viruses: These viruses primarily infect and replicate in the respiratory tract, including the nasal passages, throat, and lungs. The immune system's response needed here involves mucosal immunity, particularly in the upper respiratory tract where viruses first encounter human tissues. ๐Ÿ‘‰Intramuscular Vaccines: These are injected into the muscle, which stimulates systemic immunity. This type of immunity primarily involves circulating antibodies in the blood and systemic T-cells. While this can offer protection against infection by mobilizing an immune response throughout the body, it is less effective at directly combating pathogens at mucosal surfaces like the respiratory tract. 2. Type of Immune Response: ๐Ÿ‘‰Mucosal Immunity: For respiratory viruses, an effective defense includes IgA antibodies on mucosal surfaces, which can neutralize viruses before they enter cells. IM vaccines do not primarily induce this type of local, mucosal immune response. ๐Ÿ‘‰Systemic Immunity: IM vaccines excel at producing IgG antibodies in the blood, which are effective against systemic infections but might not reach sufficient concentrations or be in the right form (like secretory IgA) in the respiratory tract to prevent infection at the point of entry. 3. Antibody Distribution: ๐Ÿ‘‰Antibodies produced from an IM vaccine primarily circulate in the blood, with limited direct transport to the respiratory mucosa. The antibodies that do reach these areas might not be in the same concentration or form as those produced by a local (mucosal) immune response. 4. Memory and Rapid Response: ๐Ÿ‘‰While IM vaccines can create systemic memory B and T cells, the speed at which these cells can migrate to and act in the respiratory tract might not be fast enough to prevent viral replication in the initial stages of infection. Mucosal vaccines can create a more rapid, localized response. 5. Viral Replication Sites: ๐Ÿ‘‰Respiratory viruses often replicate in the epithelial cells lining the respiratory tract. An IM vaccine's immune response might not be as targeted to these specific sites compared to a vaccine administered via a route that directly stimulates mucosal immunity. 6. Durability and Cross-Protection: ๐Ÿ‘‰There's also the issue of how long immunity lasts at the site of infection. Mucosal immunity might provide a more durable barrier at the entry point for respiratory pathogens, potentially offering broader or longer-lasting protection against various strains or mutations of viruses. Conclusion: While intramuscular vaccines can still provide some level of protection against respiratory viruses by reducing disease severity or preventing systemic spread, they are less ideal for preventing the initial infection at the mucosal surfaces. This is why alternative vaccine strategies, like nasal sprays or other forms of mucosal vaccination, are often considered for better efficacy against respiratory pathogens. However, IM vaccines remain crucial due to their ease of administration, stability, and effectiveness in inducing systemic immunity, which can be vital for reducing severe outcomes even if initial infection occurs. My remarks: 1. Most infectious diseases are mucosal in nature, so most IM vaccines don't work as intended, be it the flu vaccine, HIV, or RSV. 2. At best, they can reduce severe outcomes, but the opposite can also be true. Doctors have many alternative ways og reducing severe outcomes. 3. There are many alternative ways of treating and preventing severe outcomes and by doing so, inducing natural immunity. 4. So yes, vaccines are mostly just fraud.

Gaute Adler Nilsen ๐Ÿ›‘ Shadow-๐Ÿšซ ๐Ÿ‘‰๐Ÿ’€๐Ÿง‘โ€๐Ÿคโ€๐Ÿง‘

111,058 gรถrรผntรผleme โ€ข 1 yฤฑl รถnce

Dr. Suzanne Humphries Exposes the Shocking Truth: How the Measles Vaccine Created a Hidden Epidemic of Vulnerable Adults and Babies Before the vaccine, reported measles cases were just the tip of the icebergโ€”most cases were so mild they never made it into the official records. The CDC itself admits that to achieve the 95%+ immunity seen in blood surveys, there must have been around four million annual cases in America, meaning only about one-eighth of infections were ever documented.โ€‹ Fast forward to today: adolescents and adults are now the most vulnerable group, because vaccine-induced immunity is 23.2 times weaker than immunity from natural infection. This includes maternal immunity, which means babies today are three times more susceptible than they were before vaccines.โ€‹ Experts like Dr. Papania and Dr. Peter Orbe have observed the same trend globally: as vaccination rates rise and natural virus circulation drops, measles increasingly strikes older populations, including pregnant women, with more severe outcomes. In the early days of vaccination, immunity was artificially boosted by ongoing exposure to wild measles, making vaccines appear more effective than they truly were.โ€‹ But now, with natural boosting gone and vaccine immunity waning, herd immunity is fragile. Studies predict that in 20โ€“30 years, the number of susceptible individuals could surpass pre-vaccine levels. Dr. Heffernanโ€™s analysis warns that after 52 years of vaccination programs, large-scale epidemics could eruptโ€”potentially as early as 2032 in the U.S..โ€‹ Blood tests confirm it: 20 years after two doses, 33โ€“44% of vaccinated people lose immunity. The old, lifelong community immunity of 95โ€“99% is gone. The answer from health authorities? More vaccines, earlier and more often, and even mandatory mandates from cradle to grave.โ€‹ Dr. Suzanne Humphries reminds us: the real story of measles immunity is far more complex than the official narrative. As vaccine protection fades and natural immunity disappears, the future of measles is uncertainโ€”and the risks are rising.

Camus

17,141 gรถrรผntรผleme โ€ข 9 ay รถnce